Torbjørn Bjerke
Oprichter bij Arctic Asset Management AS (Sweden)
Vermogen: 523 803 $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Torbjørn Bjerke
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
University of Aarhus
49
| College/University | Other Consumer Services | 49 |
| Public Company | Pharmaceuticals: Major | 45 | |
| Public Company | Financial Conglomerates | 21 | |
| Public Company | Trucking | 20 | |
| Public Company | Pharmaceuticals: Major | 17 | |
11
| Public Company | Pharmaceuticals: Major | 11 |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
10
| Operating Division | Investment Managers | 10 |
| Public Company | Biotechnology | 7 | |
Biolipox AB
 Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients.
3
| Operating Division | Investment Managers | 3 |
Biothea Pharma, Inc.
 Biothea Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Biothea Pharma, Inc. is an American biotechnology company that operates in the field of pharmaceuticals. The private company was founded by John F. Vavricka. Marina S. Bozilenko has been the CEO of the company since 2021.
3
| Private Company | Miscellaneous Commercial Services | 3 |
TXP Pharma AG (Switzerland)
 TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Torbjørn Bjerke via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BAXTER INTERNATIONAL INC. | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Pharmaceuticals: Major | Chief Executive Officer Chief Operating Officer | |
| ACADIA PHARMACEUTICALS INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal | |
| DEMANT A/S | Medical Specialties | Director/Board Member Director of Finance/CFO Director/Board Member | |
| ACTIVE BIOTECH AB | Biotechnology | Director/Board Member Director/Board Member Chairman | |
| MEDIVIR AB | Pharmaceuticals: Major | Director/Board Member Chairman Chief Tech/Sci/R&D Officer | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Investment Officer Chief Executive Officer Director/Board Member | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Cheminova A/S
 Cheminova A/S Chemicals: AgriculturalProcess Industries Cheminova A/S manufactures pesticides and other agrochemical products. It offers herbicides, insecticides, fungicides, seed dressings, regulants, grain protectants, and animal health products. The company was founded by Gunnar Andreasen in 1938 and is headquartered in Harboøre, Denma rk. | Chemicals: Agricultural | Director of Finance/CFO Director/Board Member | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Undergraduate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree Masters Business Admin | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chairman Chief Tech/Sci/R&D Officer | |
| University of Lund | College/University | Corporate Officer/Principal Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Sophion Bioscience A/S
 Sophion Bioscience A/S Medical SpecialtiesHealth Technology Sophion Bioscience A/S develops, manufactures and markets instruments and supplies automated patch clamping. It develops throughput patch clamp solutions for functional characterization of living cells. The firm products are used in pharmaceutical and biotech companies around the world. The company was founded in July 2007 and is headquartered in Ballerup, Denmark. | Medical Specialties | Corporate Officer/Principal Chairman Director/Board Member | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Founder | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| KCIF Fund Management AB | Chief Executive Officer Chairman Chief Executive Officer | ||
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
NovaSAID AB
 NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman Director/Board Member Chief Tech/Sci/R&D Officer | |
Confederation of Danish Industry
 Confederation of Danish Industry Miscellaneous Commercial ServicesCommercial Services Confederation of Danish Industry operates as a business and employers organization for small and medium-sized enterprises. It serves manufacturing industry as well as sectors such as transportation, energy, information technology, health, trade, and professional services. The firm specializes in negotiation of collective agreements with labor unions; local, national, and international business regulations; and support for members on numerous services and relevant networks. The company is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Palette Life Sciences AB
 Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| KD Incentive AB | Chairman Director/Board Member | ||
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Director/Board Member Director/Board Member | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Director/Board Member | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Avilex Pharma ApS
 Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Chairman | |
| SANA AB | Biotechnology | Founder Director/Board Member Founder Corporate Officer/Principal | |
| LYSOGENE | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| CERENO SCIENTIFIC AB | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Saniona A/S
 Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| IDORSIA LTD | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Gesynta Pharma AB
 Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer Founder | |
| TXP Pharma GmbH | Chief Executive Officer Founder Corporate Officer/Principal |
Statistieken
Internationaal
| Zweden | 23 |
| Denemarken | 18 |
| Frankrijk | 5 |
| Verenigde Staten | 4 |
| Zwitserland | 4 |
Sectoraal
| Health Technology | 33 |
| Commercial Services | 8 |
| Consumer Services | 5 |
| Finance | 3 |
| Process Industries | 2 |
Operationeel
| Director/Board Member | 593 |
| Corporate Officer/Principal | 207 |
| Chairman | 176 |
| Independent Dir/Board Member | 129 |
| Chief Executive Officer | 88 |
Sterkste connecties
| Insiders | |
|---|---|
| Peter Hutt | 69 |
| Peter Sjöstrand | 35 |
| Bo Jesper Hansen | 34 |
| Michael Wilhelm Rosenlew | 32 |
| Niels Jacobsen | 32 |
| Michael Shalmi | 30 |
| Michel de Rosen | 28 |
| Jeppe Øvlesen | 27 |
| Jørgen Drejer | 26 |
| Chahra Khaoua Epouse Louafi | 26 |
| Michael Owens | 25 |
| Flemming Heise Pedersen | 24 |
| Rafaèle Elisabeth Tordjman | 23 |
| Gunilla Anders Ekström | 22 |
| Thomas Hofman-Bang | 22 |
- Beurs
- Insiders
- Torbjørn Bjerke
- Bedrijfsconnecties
